Why the study?
Cardiotoxicity is a major treatment-related toxicity in breast cancer patients, but the real magnitude of the problem remains unclear and research into mitigation or management strategies is limited.
This review highlights the agents causing cardiotoxicity in breast cancer treatment and proposes follow-up strategies to mitigate its impact on survivors' quality of life.
Answers are grounded in this paper and cite their sources.
Proposal for breast cancer survivor follow-up is hypothesis-generating; leaves open optimal cardio-oncology surveillance pending prospective validation.
Survivorship issues and treatment related toxicities have considerably increased in breast cancer patients following improved therapeutic options. Cardiotoxicity has been a major treatment related side effects in these patients. Despite this being a well-known entity, the real magnitude of the problem remains an enigma. The amount of research in mitigation of cardiotoxicity or its management in breast cancer survivors is limited and there is an urgent need for finding solutions for the problem. In this article, we are reviewing the agents that cause cardiotoxicity and suggesting a proposal for follow up of breast cancer survivors in an attempt to reduce the magnitude of impact on their quality of life.
No takes yet. Share an insight, caveat, or question.
Valiyaveettil et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: